Without an experimental model of Equine Grass Sickness (EGS), a randomised controlled 23 field trial (RCT) represents the only method of evaluating the efficacy of Clostridium botulinum type 24 C vaccination in preventing naturally occurring disease. Clinical trial feasibility is an important aspect 25 of preliminary work undertaken prior to initiating RCTs, estimating parameters that are important for 26 study design. This cross-sectional study aimed to assess the feasibility of conducting a nationwide 27 RCT of a candidate vaccine for EGS based on responses from a sample of British equine veterinary 28 practices (n = 119/284). 29 30 Seventy-three percent of practices had attended ≥ 1 EGS case within the preceding two years 31 (median four cases), and 51.3% regularly attended recurrently affected premises. Veterinary surgeons 32 had greater confidence diagnosing acute/subacute EGS based solely on history and clinical signs 33
Introduction 47
Equine grass sickness (EGS) is a predominantly fatal neurodegenerative disease affecting 48 grazing equids, first described in eastern Scotland in the early 1900s (Tocher et al., 1923) . Britain 49 continues to have the highest incidence of EGS worldwide (Wylie and Proudman, 2009), with 50 reported incidence rates of 2.1-2.3 cases per 100 horse-years at risk on EGS-affected premises 51 Ireland et al., 2011) and an estimated prevalence of 3.2% in areas of Scotland 52 (Doxey et al., 1991a) . 53 54 It is hypothesised that EGS represents a toxico-infectious form of botulism, with a 55 combination of risk factors resulting in intestinal overgrowth of and neurotoxin production from 56
Clostridium botulinum (C. botulinum) type C (Newton et al., 2010) . Randomised placebo-controlled 57 vaccine field trials conducted in 1922-1923, using an antitoxin-neutralised C. botulinum toxin, 58 demonstrated a marked reduction in EGS incidence in vaccinated animals (Tocher, 1924) . Lower 59 serum antibody titres to C. botulinum type C surface antigens and C. botulinum C1 neurotoxin 60 (BoNT/C) were identified in EGS cases compared to controls (Hunter et al., 1999 ) and a subsequent 61 case-control study reported that increasing antibody titres to C. botulinum type C and BoNT/C toxoid 62 were significantly associated with decreased risk of EGS (McCarthy et al., 2004) . Additionally, horses 63 previously in contact with an EGS case were reported to be at reduced risk, potentially indicating that 64 non-fatal exposure to the causative agent may induce some degree of resistance (Wood et al., 1998) . 65
Currently, there is no model to reproduce EGS experimentally, precluding the use of experimental 66 challenge studies and therefore a field trial represents the only available method to test the hypothesis 67 that C. botulinum type C toxico-infection causes EGS and of evaluating the effect of vaccination in 68 the prevention of naturally occurring disease . 69
70
The randomised controlled trial (RCT) is considered as the best instrument to evaluate the 71 effectiveness of medical interventions (Oude Rengerink et al., 2010) . Clinical trial feasibility is a 72 process of evaluating the possibility of conducting a particular trial in a specific geographical region 73 (Rajadhyaksha, 2010) , and is an important first step in initiating a RCT. In human clinical trials, 74 investigator/site selection questionnaires and feasibility checklists are frequently employed to identify 75 potential trial sites and participants. Feasibility studies are considered to be particularly important for 76
RCTs investigating interventions for rare diseases (Hickey et al., 2010) . 77
78
In order to inform the design of a nationwide randomised, placebo-controlled field trial of a 79 candidate vaccine against EGS in Britain, this cross-sectional feasibility study aimed to identify 80 practices attending premises with high EGS incidence rates and to explore attitudes of veterinary 81 surgeons towards the proposed RCT. 82 83
Materials and methods 84

Selection of study sample 85
Non-probability sampling was used, with all veterinary practices (n = 200) registered with a 86 nationwide EGS surveillance scheme covering England, Scotland and Wales (Wylie et al., 2011) 87 being invited to participate. Additionally, from the database of referring veterinary practices held by 88 the Diagnostic Laboratory Services at the Animal Health Trust, a further 84 practices (located in 89
England, Scotland and Wales) with equine clients were identified and the principal partners were 90 invited to participate. 91 92
Questionnaire design 93
The self-administered postal questionnaire was designed using an automated data capture 94 system (Autonomy, TeleForm version 10.2) (Supplementary material 1). The questionnaire contained 95 a study synopsis pertaining to the proposed protocol for a nationwide RCT of a candidate vaccine for 96 EGS. The questionnaire was pretested amongst a group of veterinary surgeons, who were not enrolled 97 on the study, and revised in accordance with their comments. The questionnaire was accompanied by 98 a reply-paid envelope and a hand-signed covering letter that assured confidentiality and provided the 99 principal investigator's name, address, telephone number and email address. To maximise response 100 rates, reminder postcards were sent to non-respondents 8 weeks after the initial mailing, followed by a 101 second questionnaire mailing 6 weeks after the reminder postcards to remaining non-respondents. 102 103
Data analysis 104
Questionnaire data were scanned and verified using TeleForm then exported to Microsoft 105
Excel. Statistical analyses were performed using commercial software (SPSS version 21). Data are 106 described as medians with interquartile ranges (IQR) for continuous data and as proportions with 95% 107 confidence intervals (CI) for categorical data. Pearson Chi-squared or Fisher's exact tests were used to 108 assess associations between categorical variables. Kruskal-Wallis or Mann-Whitney U tests were 109 used to test the statistical significance of differences in median values of continuous variables 110 between categories of categorical variables. Critical probability was set at 0.05. 111
112
Results 113
Description of responses 114
Of the 284 questionnaires mailed, 119 useable responses (41.9%) were returned, with a 115 further three non-useable responses received from practices declining to participate due to limited 116 numbers of EGS cases seen by the practice. Detailed descriptions of responses and characteristics of 117 responding practices are available as supplementary information (items 2 and 3). Comparison of 118 respondents with non-respondents found no association between response rate and country (England, 119 Scotland or Wales) (P = 0.40), type of practice (P = 0.13) or registration with the EGS surveillance 120 scheme (P = 0.10). 121
122
Of the 119 responding practices, 2.5% (n = 3; 0-5.3%) no longer undertook equine work, and 123 these responses were excluded from further data analysis. Thirty-eight percent (n = 44/116; 29.1-124 46.8%) of practices were equine-only; 49.1% (n = 57; 40.0-58.2%) were mixed practices with < 50% 125 equine work and 12.9% (n = 15; 6.8-19.0%) were mixed practices with ≥ 50% equine work. The 126 majority were first opinion practices (69.8%; n = 81; 61.5-78.2%). The number of registered 127 horses/ponies differed with proportion of equine work: equine-only practices had a median of 5,250 128 horses/ponies (IQR 2,075-10,000), mixed practices with ≥ 50% equine work had a median of 4,812 129 horses/ponies (IQR 1,500-13,684) and mixed practices with < 50% equine work had a median of 130 1,000 horses/ponies (IQR 358-2,000) (P < 0.001). 131 132
Veterinary surgeon experience of EGS 133
The majority of respondents reported that their practice had attended ≥ 1 EGS case within the 134 preceding two years (73.0%; n = 84/115; 64.9-81.1%; Figure 1 reported attending ≥ 1 EGS case within the preceding two years compared to mixed practices (61.6%; 137 n = 45/73; 50.5-72.8%) (P = 0.002). Using the estimated total number of registered horses/ponies, the 138 median EGS period prevalence for the preceding two years was 0.08% (IQR 0.005-0.25%; range 0-139 3.0%). The period prevalence in Scotland was higher (median 0.5%; IQR 0.25-1.0%) compared to 140
England (median 0.05%; IQR 0.005-0.17%) or Wales (median 0.03%; IQR 0.005-0.07%) (P = 0.005). 141
Excluding practices reporting no EGS cases in the previous two years, the median period prevalence 142 was 0.12% (IQR 0.02-0.3%; range 0.009-3.0%). 143
The majority of respondents indicated they could readily identify premises attended by their 145 practice that had been affected by EGS within the preceding two years (68.8%; n = 77/112; 60.2-146 77.3%), with a greater proportion of equine-only practices (81.0%; n = 34/42; 69.1-92.8%) able to 147 identify EGS-affected premises compared to mixed practices (61.4%; n = 43/70; 50.0-72.8%) (P = 148 0.03). Fifty-one percent of respondents (n = 56/109; 42.0-60.8%) indicated their practice regularly 149 attended premises recurrently affected by EGS. There was an association between country and 150 recurrent premises (P = 0.001), with 92.3% of practices in Scotland (n = 12/13; 77.8-100%) able to 151 identify recurrent premises, compared to 47.8% of practices in England (n = 44/92; 37.6-58.0%) and 152 none of the practices in Wales (n = 0/4; 0-0.49%). 153
154
The majority of respondents reported that their practice provided recommendations for 155 management on EGS-affected premises. The most frequently recommended preventive management 156 strategies were minimising pasture disturbance, removal of horses/ponies from affected fields for a 157 specified period of time and prioritising preventive measures at high risk times of year and/or for high 158 risk groups of horses/ponies (Table 1) . 159
160
Respondents indicated that veterinary surgeons within their practice were more confident 161 diagnosing the acute or subacute clinical subtypes of EGS based solely on history and clinical signs 162 compared to cases of chronic EGS (Table 2) . For diagnosis of acute/subacute EGS, a greater 163 proportion of respondents from equine-only practices (81.4%; n = 35/43; 69.8-93.0%) indicated that 164 veterinary surgeons within their practice were confident/very confident based solely on history and 165 clinical signs compared to respondents from mixed practices (63.0%; n = 46/73; 51.9-74.1%) (P = 166 0.04). Similarly, for diagnosis of chronic EGS, a greater proportion of respondents from equine-only 167 practices (69.8%; n = 30/43; 56.0-83.5%) indicated that veterinary surgeons within their practice were 168 confident/very confident based solely on history and clinical signs compared to respondents from 169 mixed practices (45.1%; n = 32/71; 33.5-56.6%) (P = 0.01). For diagnosis of acute/subacute EGS, the 170 median number of EGS cases attended within the preceding two years was greater where veterinary 171 surgeons were reported to be confident/very confident compared to those reported to be not/somewhat confident (median 4 cases, IQ 2 -7 cases and median 2, IQ 0 -3 cases, respectively) (P < 0.001). 173
The median number of EGS cases attended within the preceding two years was also greater where 174 veterinary surgeons were reported to be confident/very confident in the clinical diagnosis of chronic 175 EGS compared to those reported to be not/somewhat confident (median 5 cases, IQ 2 -9 cases and 176 median 2, IQ 0 -4 cases, respectively) (P < 0.001). The most frequently reported ante-mortem 177 ancillary diagnostic tests used in the investigation of suspected cases of EGS were phenylephrine eye 178 drops and routine haematology and biochemistry (Table 2) . 179 180
Potential participation in EGS vaccine RCT 181
When asked about the feasibility of undertaking certain aspects of clinical assessments, 182 treatment administration and data collection, the majority of respondents indicated that the proposed 183 RCT protocol would be feasible (Table 3) . were: the RCT was not relevant to practice caseload/low EGS incidence (n = 4); they did not believe 207 clients would wish to participate (n = 3); they considered that there would be too much paperwork 208 involved (n = 2); the RCT was too great a time commitment (n = 1); they were not interested in the 209 RCT/EGS (n = 1); concerns over causal association between C. botulinum type C and EGS and 210 limited available safety data (n = 1); and forthcoming personnel changes at the practice (n = 1). 211 With the aim of maximising response rate and minimising non-response bias, many elements 233 of the tailored design method (Dillman, 2007) were utilised in the administration of this survey. 234
These included the use of personalised cover letters, sending questionnaires by first class post and 235 providing non-respondents with a second copy of the questionnaire, which were all reported in a 236 systematic review as methods that significantly increase response rates to postal questionnaires 237 (Edwards et al., 2002) . The risk of errors introduced by responder bias is a well-recognised limitation 238 of all questionnaire-based research and in this study respondents are likely to be individuals with a 239 particular interest in EGS, and not, therefore, a representative sample of the equine veterinary 240 profession in the UK. Although not statistically significant, comparison of respondents with non-241 respondents identified that a greater proportion of practices registered with the EGS surveillance 242 scheme responded than other practices invited to participate in the study. However, it is unlikely that 243 practices rarely attending cases of EGS would elect to register with the surveillance scheme and 244 practices in regions with lower EGS incidence are likely to be under-represented in this study. 245
Although this degree of response bias precludes direct extrapolation of this study's findings to all 246 veterinary practices undertaking equine work in Britain, it does support use of the surveillance scheme 247 in recruiting practices as site investigators for the proposed EGS RCT. 248
249
Both equine-only and mixed practices were represented in the study population, with the 250 majority of respondents working in solely first opinion practices. As might be expected, equine-only 251 practices had greater numbers of registered horses, and a larger proportion had attended EGS cases 252 within the study period. Ante-mortem diagnosis of EGS is often presumptive, based on a combination 253 of historical epidemiological information and clinical signs. However clinical signs exhibited are 254 often diverse, varying with disease severity, and no clinical sign is pathognomonic for all forms of the 255 disease (Doxey et al., 1991b ). In addition, many of the clinical signs observed may also occur in a 256 substantial proportion of colic cases (Doxey et al., 1991b) , and it may be difficult to differentiate 257 acute/subacute EGS from other causes of colic particularly in areas where the disease is less prevalent 258 (Milne, 1996) . In this study, respondents indicated a greater degree of confidence making a clinical 259 diagnosis of acute/subacute EGS compared to cases of chronic EGS. Veterinary surgeons from 260 equine-only practices were more confident in the clinical diagnosis of EGS compared to those from 261 mixed practices, which may reflect the increased likelihood of these respondents having recent 262 experience of the disease. Furthermore, veterinary surgeons that were confident in diagnosing EGS 263 based solely on history and clinical signs had attended a greater number of EGS cases within the 264 preceding two years. 265
266
Prevalence of EGS was greatest in Scotland, consistent with historical reports (Guthrie, 1940; 267 Gilmour and Jolly, 1974) , and in keeping with more recent data, a significantly greater proportion of 268
Scottish practices regularly attended EGS-affected premises with a history of disease recurrence 269 EGS-affected premises, predominantly pertaining to pasture management, reducing access to the 285 EGS-affected paddock and prioritising preventive management strategies for high risk animals, and 286 particularly where respondents had attended EGS cases within the preceding 2 years. Premises where 287 pasture had been disturbed, for example through construction work or moles, within the previous 12 288 months had higher odd of an EGS case occurring compared to pastures that had not been disturbed 289 preventive management strategies for animals within these higher risk groups. It is likely that a 299 substantial proportion of EGS-affected premises will implement preventive management strategies in 300 order to try to reduce the risk of recurrence. his needs to be taken into consideration as a potential bias 301 when designing protocols for any intervention for EGS, including a vaccine RCT. An appropriately 302 conducted RCT, with random treatment group allocation performed at premises level, would facilitate 303 controlling for these management-level risk factors. 304
305
Poor investigator compliance with trial protocols can have important effects on the overall 306 result (Prescott et al., 1999) . Poor design of data collection methods, excessive data collection and 307 follow-up have been cited by clinicians as impediments to patient recruitment in human trials (Benson 308 et al., 1991; Coombs et al., 1993 ). In the current study, of the small number of respondents not willing 309 to participate in the proposed EGS RCT, 25% considered that there would be too much paperwork 310 involved. The majority of respondents indicated that data collection, clinical assessments and 311 treatment administration aspects of the proposed RCT protocol would be feasible for their practice to 312 undertake ( Table 3) , implying that attaining good compliance with the trial protocol would be 313 achievable. A substantial proportion of respondents indicated that provision of clerical support or 314 additional remuneration would be required for data collection, and that availability of veterinary 315 support for the treatment administration phase would be desirable. Ensuring these factors are 316 considered in both the design and financial requirements for the proposed RCT will help to maximise 317 veterinary investigators' compliance with the trial protocol. 318
319
In a survey of healthcare professionals, 17% indicated that scientifically uninteresting trials 320
were an impediment to recruitment (Foley and Moertel, 1991) . Questions addressed by RCTs should 321 be interesting and relevant to practice (Fletcher et al., 2012) and of sufficient importance to clinicians 322 for them to be willing to take part and comply with protocol requirements (Prescott et al., 1999) . 323
While only 49% of respondents in the current study considered a nationwide RCT of a candidate 324 vaccine against EGS would be important to their own practice, 91% considered that this RCT would 325 be important to equine veterinary research. 326
327
The majority of respondents indicated willingness to assist in recruitment of horse owners for 328 the proposed RCT, and a large proportion indicated that they would recommend participation to 329 owners registered with their practice should one of their clients enrol in the trial. The reasons given by 330 those not wishing to aid in the recruitment phase were consistent with factors frequently reported to 331 act as barriers to the recruitment activity of clinicians in human clinical trials (Prescott et al., 1999; 332 Ross et al., 1999) . In order to assess the overall acceptability of the proposed RCT, respondents were 333 asked whether or not they would enrol their own animal, or a horse/pony owned by a family member 334 or close friend, with the majority responding positively to both scenarios. 335 336 Ninety-three percent of respondents indicated willingness to participate in the RCT, with a 337 greater proportion indicating that they would take part should a client wish to enrol. Most respondents 338 to the current study indicated that they would recommend the use of vaccination in the prevention of 339 EGS, should an effective vaccine be available. As with barriers to recruitment, reasons given by respondents for not wishing to participate in the proposed RCT were broadly similar to factors 341 affecting clinician decisions regarding taking part in clinical trials (Prescott et al., 1999; Ross et al., 342 1999) . Clinician concerns about adverse effects of treatment or the burden to patients were cited as 343 important factors in deciding whether or not to take part in cancer clinical trials (Foley and Moertel, 344 1991) . While these factors were considered important barriers by a very low number of respondents in 345 this study, ensuring safety data are available and addressing protocol-related barriers to owner 346 participation should be incorporated in the design of the proposed RCT. Table 3 : Veterinary surgeons' opinions regarding aspects of data collection, clinical assessment and 532 treatment administration for a proposed RCT of a vaccine for the prevention of EGS reported in a 533 survey of veterinary surgeons in Britain (n=116). 534
